Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-α Inadequate Response Mechanisms.
| Autor: | Wang, Jing, Macoritto, Michael, Guay, Heath, Davis, Justin W, Levesque, Marc C, Cao, Xiaohong |
|---|---|
| Zdroj: | Inflammatory Bowel Diseases; May2023, Vol. 29 Issue 5, p771-782, 12p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|